No

Dopamine Agonist

Treatment of severe hypertension particularly I.V. and in patients with renal compromise; potential use for congestive heart failure

Hypersensitivity of fenoldopam or any component; hypersensitivity to sulfites (contains sodium metabisulfite)

Use caution in patients with glaucoma or intraocular hypertension. A dose-related tachycardia can occur, especially at infusion rates >0.1 mcg/kg/minute. Use caution in angina patients (can increase myocardial oxygen demand with tachycardia). Close monitoring of blood pressure is necessary (hypotension can occur). Monitor for hypokalemia at intervals of 6 hours during infusion. Safety and effectiveness in children have not been established. For continuous infusion only (no bolus doses). The effects of of hemodialysis on the pharmacokinetics of fenoldopam have not been evaluated.

Percentage unknown: Hypotension, edema, tachycardia, facial flushing, asymptomatic T-wave flattening, flutter (atrial), fibrillation (atrial), chest pain, angina in patients with history of unstable angina, headache, dizziness, nausea, vomiting, diarrhea, xerostomia, intraocular pressure (increased), blurred vision, increases in portal pressure in cirrhotic patients

Concurrent acetaminophen may increase fenoldopam levels (30% to 70%).

Beta-blockers increase the risk of hypotension.

Store ampuls at room temperature; diluted solution is stable for less than or equal to 24 hours; discard any diluted solution that is not used after 24 hours

A selective postsynaptic dopamine agonist (D₁-receptors) which exerts hypotensive effects by decreasing peripheral vasculature resistance with increased renal blood flow, diuresis, and natriuresis; 6 times as potent as dopamine in producing renal vasodilitation; has minimal adrenergic effects

Onset of action: I.V.: 10 minutes

Duration: Oral: 2-4 hours; I.V.: 1 hour

Absorption: Oral: Good, however, undergoes extensive first-pass metabolism; peak serum levels at 1 hour after oral doses

Distribution: V_d: 0.6 L/kg

Half-life: I.V.: 9.8 minutes

Metabolism: Hepatic to multiple metabolites; the 8-sulfate metabolite may have some activity

Elimination: Renal (80%), fecal (20%)

I.V.: Severe hypertension: Initial: 0.1 mcg/kg/minute; may be increased in increments of 0.05-0.2 mcg/kg/minute until target blood pressure is achieved; average rate: 0.25-0.5 mcg/kg/minute; usual length of treatment is 1-6 hours with tapering of 12% every 15-30 minutes

Dosing adjustment in hepatic impairment: None published

Blood pressure, heart rate, EKG, renal/hepatic function tests

Mean plasma fenoldopam levels after a 2 hour infusion (at 0.5 mg/kg/minute) and a 100 mg dose is approximately 13 ng/mL and 50 ng/mL

May cause dizziness

Causes hypotension; caution with low potency antipsychotics and TCAs

No information available to require special precautions

No effects or complications reported

Injection: 10 mg/mL (5 mL)